The event will feature a presentation from Key Opinion Leader David G. Warnock, MD (University of Alabama at Birmingham) who, along with the Protalix Biotherapeutics management team, will discuss the positive topline results from the company’s Phase III BALANCE clinical trial of PRX-102, a PEGylated enzyme replacement therapy with potentially two different dosing regimens, for the treatment of Fabry disease.

A live question and answer session will follow.